FDA updates oral nizoral label to reflect safety concerns

FDA updates oral nizoral label to reflect safety concerns
The U.S. Food and Drug Administration has approved label changes for Nizoral (ketoconazole) oral tablets and added a Medication Guide detailing various associated safety concerns.

(HealthDay)—The U.S. Food and Drug Administration has approved label changes for Nizoral (ketoconazole) oral tablets and added a Medication Guide detailing various associated safety concerns.

Nizoral tablets can cause , potentially necessitating transplantation or resulting in death. The Boxed Warning has been revised to include a strong recommendation against its use in patients with liver disease, and new recommendations for assessing and monitoring for . Nizoral can cause adrenal insufficiency by decreasing production of corticosteroids; should monitor adrenal function in patients taking Nizoral who have existing adrenal problems or who are under prolonged periods of stress. The precautions section of the drug label has been updated to include information of potential drug interactions. The FDA has also approved a Medication Guide with information on the potential risks linked with oral Nizoral use. Topical formulations of Nizoral have not been associated with liver damage, adrenal problems, and drug interactions.

Oral Nizoral tablets should no longer be a first-line treatment for any fungal infection, and should only be used for endemic mycoses when alternative antifungal therapies are unavailable or not tolerated. Use of Nizoral tablets should be limited by removing indications where the risks outweigh the benefits of treatment.

"[We] will continue to evaluate the safety of Nizoral tablets and will communicate with the public again if additional information becomes available," according to the FDA.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

FDA reports Samsca may cause liver damage

May 02, 2013

(HealthDay)—After reviewing data from recent large clinical trials, the U.S. Food and Drug Administration has determined that Samsca (tolvaptan) should not be used for longer than 30 days and should not ...

FDA: Samsca may cause irreversible liver damage

Jan 26, 2013

(HealthDay)—Patients who take Samsca (tolvaptan) may be at elevated risk for significant liver injury, according to a Jan. 25 safety alert issued by the U.S. Food and Drug Administration.

Signifor approved for Cushing's disease

Dec 17, 2012

(HealthDay)—Signifor (pasireotide diaspartate) has been approved by the U.S. Food and Drug Administration to treat Cushing's disease in cases that cannot be treated by surgery.

Aubagio approved for multiple sclerosis

Sep 13, 2012

(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

Recommended for you

FDA to start regulating lab-developed tests

13 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments